Nine million Americans live with a chronic cough that persists despite treatment or has no identifiable cause. Chronic cough is one of the most common reasons people visit a physician in the U.S., and remains one of the least effectively treated conditions with no new therapies approved in more than 60 years. Nocion’s mission is to change that. We are developing taplucainium, a first-in-class inhaled therapy designed to silence the nerve signaling that drives refractory and unexplained chronic cough at its source. Nocion is also leveraging its foundational scientific platform to develop new medicines to address other debilitating chronic conditions where overactive sensory nerves cause lasting harm.
